Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Leukemia

Free Subscription 22.04.2019 1 Am J Clin Pathol 2 Ann Hematol 2 Blood 1 BMC Cancer 1 BMJ 1 Bone Marrow Transplant 1 Cancer 3 Exp Hematol 1 J Clin Oncol 1 J Immunol 2 J Pediatr Hematol Oncol 1 J Virol 2 Leuk Lymphoma 1 Leuk Res 2 N Engl J Med 1 Oncol Rep 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Pathol

1. AL MUGAIRI A, Al Turki S, Salama H, Al Ahmadi K, et al
   Isolated Bone Marrow Non-Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia.
   Am J Clin Pathol. 2019 Apr 16. pii: 5467236. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Hematol

2. WANG Z, Yin C, Zhang W, Tang W, et al
   The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
   Ann Hematol. 2019 Apr 16. pii: 10.1007/s00277-019-03682.
   PubMed     Text format     Abstract available
   
   
3. ZHANG X, Guo X
   Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
   Ann Hematol. 2019 Apr 12. pii: 10.1007/s00277-019-03674.
   PubMed     Text format    
   
   

   
   Blood

4. PLESA A, Sujobert P
   Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion.
   Blood. 2019;133:1789.
   PubMed     Text format    
   
   
5. YIN M, Chung YJ, Lindsley RC, Walker RL, et al
   Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.
   Blood. 2019 Apr 16. pii: blood.2018864173. doi: 10.1182/blood.2018864173.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

6. PARK H, Youk J, Shin DY, Hong J, et al
   Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
   BMC Cancer. 2019;19:358.
   PubMed     Text format     Abstract available
   
   

   
   BMJ

7. 
   Seven days in medicine: 16-22 January 2019.
   BMJ. 2019;364:l320.
   PubMed     Text format    
   
   

   
   Bone Marrow Transplant

8. MASCHAN M, Shelikhova L, Ilushina M, Shekhovtsova Z, et al
   Outcome of alphabeta T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission.
   Bone Marrow Transplant. 2019 Apr 15. pii: 10.1038/s41409-019-0531.
   PubMed     Text format    
   
   

   
   Cancer

9. JABBOUR EJ, Sasaki K, Ravandi F, Short NJ, et al
   Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblas
   Cancer. 2019 Apr 15. doi: 10.1002/cncr.32139.
   PubMed     Text format     Abstract available
   
   

   
   Exp Hematol

10. XU LS, Francis A, Turkistany S, Shukla D, et al
    ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B cell acute lymphoblastic leukemia.
    Exp Hematol. 2019 Apr 12. pii: S0301-472X(19)30134.
    PubMed     Text format     Abstract available
    
    
11. GUILLAUME T, Dehame V, Chevallier P, Peterlin P, et al
    Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
    Exp Hematol. 2018 Dec 26. pii: S0301-472X(18)30987.
    PubMed     Text format     Abstract available
    
    
12. SHAPIRA S, Raanani P, Samara A, Nagler A, et al
    Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34(+)CD38(-) cells through iron chelation, induction of ROS, and inhibition of HIF1alpha expression.
    Exp Hematol. 2019;70:55-69.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

13. SHARMAN JP, Coutre SE, Furman RR, Cheson BD, et al
    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2019 Apr 17:JCO1801460. doi: 10.1200/JCO.18.01460.
    PubMed     Text format     Abstract available
    
    

    
    J Immunol

14. GUPTA R, Li W, Yan XJ, Barrientos J, et al
    Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.
    J Immunol. 2019 Apr 15. pii: jimmunol.1801142. doi: 10.4049/jimmunol.1801142.
    PubMed     Text format     Abstract available
    
    

    
    J Pediatr Hematol Oncol

15. YAMANAKA J, Shimizu M, Sato M, Inoue M, et al
    A Case of Childhood Blastic Phase Chronic Myeloid Leukemia With Minor BCR-ABL.
    J Pediatr Hematol Oncol. 2019 Apr 15. doi: 10.1097/MPH.0000000000001488.
    PubMed     Text format     Abstract available
    
    
16. DUFFY C, Hall L, Godown J, Koyama T, et al
    Steroid-induced Bradycardia During Induction Chemotherapy in Children and Young Adults Diagnosed With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    J Pediatr Hematol Oncol. 2019 Apr 15. doi: 10.1097/MPH.0000000000001483.
    PubMed     Text format     Abstract available
    
    

    
    J Virol

17. MIYAKE A, Kawasaki J, Ngo H, Makundi I, et al
    The reduced folate carrier: an entry receptor for a novel feline leukemia virus variant.
    J Virol. 2019 Apr 17. pii: JVI.00269-19. doi: 10.1128/JVI.00269.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

18. TOTH LN, Green D, Peterson J, Deharvengt SJ, et al
    Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
    Leuk Lymphoma. 2019 Apr 18:1-8. doi: 10.1080/10428194.2019.1587757.
    PubMed     Text format     Abstract available
    
    
19. GOMEZ-ARTEAGA A, Margolskee E, Wei MT, van Besien K, et al
    Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Leuk Lymphoma. 2019 Apr 18:1-6. doi: 10.1080/10428194.2019.1594220.
    PubMed     Text format    
    
    

    
    Leuk Res

20. MOSHAVER B, Wouters RF, Kelder A, Ossenkoppele GJ, et al
    Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Leuk Res. 2019;81:27-34.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

21. BERG DD, Kirshenbaum J, Gay E, Vaidya A, et al
    A Dangerous Detour.
    N Engl J Med. 2019;380:e18.
    PubMed     Text format    
    
    
22. BERG DD, Kirshenbaum JM, Gay E, Miller AL, et al
    A Dangerous Detour.
    N Engl J Med. 2019;380:1360-1365.
    PubMed     Text format    
    
    

    
    Oncol Rep

23. BAI J, Li L, Li Y, Chen Q, et al
    Methylation of the promoter region of the MTRR gene in childhood acute lymphoblastic leukemia.
    Oncol Rep. 2019 Apr 12. doi: 10.3892/or.2019.7114.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

24. SANDNER AS, Weggel R, Mehraein Y, Schneider S, et al
    Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.
    PLoS One. 2019;14:e0215453.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

25. CHEN XJ, Zhang WN, Chen B, Xi WD, et al
    Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-kappaB repressing factor.
    Proc Natl Acad Sci U S A. 2019;116:2220-2225.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: